ArticleMaterials today. Bio2025
Sophora flavescens-derived extracellular vesicles loaded with oncolytic vaccinia virus/IR1061 for NIR-II photoacoustic imaging guided multimodal treatment of diffuse large B-cell lymphoma.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, characterized by high heterogeneity and significant clinical challenges. Despite the widespread adoption of the R-CHOP regimen as the standard treatment, approximately 30 %-40 % of patients experience relapse, necessitating the development of novel therapeutic strategies. Here, we presented a multifunctional therapeutic platform combining oncolytic vaccinia virus (OVV) and the second near-infrared (NIR-II) fluorescent dye IR1061, encapsulated within Sophora flavescens-derived extracellular vesicles (SFNPs), termed SFOVV@IR1061. The OVV exhibits selective tropism for tumor cells, inducing targeted lysis while concurrently stimulating robust antitumor immune responses. In parallel, IR1061 serves a dual function, showing high-resolution tumor visualization through photoacoustic imaging while simultaneously enabling precise photothermal therapy (PTT) via its exceptional photothermal conversion efficiency. Utilizing SFNPs as a bioinspired coating improves the stability and tumor-targeting efficiency of OVV while mitigating off-target effects. In vitro and in vivo studies demonstrate that SFOVV@IR1061 effectively promotes tumor cell apoptosis by inducing immunogenic cell death (ICD) and activating innate and adaptive immune responses. The synergistic combination of OVV-mediated oncolysis and IR1061-driven PTT enhance the therapeutic efficacy and minimize systemic toxicity, which underscores the potential of SFOVV@IR1061 as a promising multimodal therapeutic approach for improving outcomes in DLBCL treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.